Ivanets N N, Kinkul'kina M A, Avdeeva T I
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(6):37-41.
One hundred and fifty psychiatrists from 61 clinics of 30 cities located in 8 regions of the Russian Federation took part in the study. The study included 896 patients treated with sertindole. The duration of illness was from 1 month to 50 years (mean 9,55 ± 8,21), a number of previous relapses varied from 0 to 20 and more (mean 5,79 ± 6,68). Each patient was followed up for 6 weeks. Patient's state was assessed clinically and with the CGI. The statistically significant improvement was seen from the first week of treatment and the percentage of patients with marked mental disorders was constantly decreased from the first to the 6th week. It has been concluded that sertindole is an effective drug for stopping psychotic symptoms in the real practice of treatment of schizophrenic patients. It is well-tolerated and allows to reduce a number of concurrent drugs used for treatment.
来自俄罗斯联邦8个地区30个城市61家诊所的150名精神科医生参与了该研究。该研究纳入了896例使用舍吲哚治疗的患者。病程为1个月至50年（平均9.55±8.21），既往复发次数从0次至20次及以上不等（平均5.79±6.68）。每位患者随访6周。通过临床和临床总体印象量表（CGI）评估患者状态。从治疗第一周起就观察到有统计学意义的改善，且从第一周到第六周，有明显精神障碍的患者百分比持续下降。得出的结论是，在精神分裂症患者的实际治疗中，舍吲哚是一种有效控制精神病症状的药物。它耐受性良好，并可减少治疗中使用的多种合并用药。
